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Abstract 
Using a proteomic analysis of human hepatocellular carcinoma (HCC), we identified the over-
expression in 4 tumors of RUVBL2, an ATPase and putative DNA helicase, known to interact 
with β-catenin and c-myc. RUVBL2 expression was further analyzed in tumors with 
quantitative RT-PCR and immunohistochemistry; in addition, RUVBL2 expression in HuH7 
cell line was silenced by siRNA or increased using a lentiviral vector. RUVBL2 mRNA over-
expression was confirmed in 72 out of 96 HCC cases and it was associated with poorly 
differentiated tumors (p=0.02) and to a poor prognosis (p=0.02), but not with β−catenin 
mutations or c-myc levels. Whereas RUVBL2 was strictly nuclear in normal hepatocytes, 
tumoral hepatocytes exhibited an additional cytoplasmic staining. There was no mutation in 
the coding sequence of RUVBL2 in 10 sequenced cases. Silencing RUVBL2 in HuH7 HCC 
cells reduced cell growth (p< 0.001) and increased apoptosis as shown by DNA fragmentation 
(p<0.001) and caspase 3 activity (p< 0.005). This was associated with an increased expression 
of several pro-apoptotic genes, and with an increased conformational activation of Bak-1 and 
Bax. On the other hand, HuH7 cells with overexpression of RUVBL2 grew better in soft agar 
(p< 0.03), had an increased resistance to C2 ceramide-induced apoptosis (p< 0.001) and gave 
rise to significantly larger tumors when injected to immunodeficient Rag2/γc mice (p = 
0.016). In conclusion, RUVBL2 is overexpressed in a large majority of HCC. RUVBL2 
overexpression enhances tumorigenicity and RUVBL2 is required for tumor cell viability. 
These results argue for a major role of RUVBL2 in liver carcinogenesis. 
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Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer. Despite the 
discovery of several carcinogenetic pathways, the mechanisms of liver carcinogenesis are still 
unclear (1). It is also apparent that the underlying mechanisms may be different according to 
the etiology of the HCC (2, 3). Due to its high incidence in occidental countries, hepatitis C is 
responsible for a strong increase in HCC incidence. As several other groups (4, 5), we have 
recently applied proteomics technology to discover new markers or targets in HCV-related 
HCC. This was done using 2D-electrophoresis and mass spectrometry and led to the 
discovery of many regulated proteins (6) including the recently uncovered protein RUVBL2, 
also known as TIP49b (7), TIP48 (8), Reptin52 (9), Rvb2 (10), TAP54β (11), ECP-51 (12) 
and TIH2p (13). RUVBL2 contains the Walker A and Walker B motifs which are found in 
proteins that bind and hydrolyze ATP (14). RUVBL2 also has limited homology to the 
bacterial RuvB ATP-dependent DNA helicase. Human RUVBL2 has indeed been shown to 
have ATPase activity (7, 11) whereas its DNA helicase activity has been disputed (7, 11). 
RUVBL2 is found in several nuclear high molecular weight chromatin-remodeling complexes 
(10, 11). Recently, it was found that RUVBL2 was able to interact with β-catenin resulting in 
altered TCF/LEF-mediated transcription (9, 15). RUVBL2 also interacts with a domain of c-
myc required for oncogenic transformation (8) and its expression is controlled by c-myc itself 
(8, 16). Given that β-catenin and c-myc are two key actors of liver carcinogenesis, our study 
was designed to assess the role of RUVBL2 in liver carcinogenesis. 
 
Experimental procedures 
Liver samples  
Samples came from resected or explanted livers with HCC of patients treated in Bordeaux 
from 1992 to 2005. Fragments of fresh tumoral and non-tumoral liver tissues (taken at a 
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distance of at least 2 cm from the tumor) were immediately snap-frozen in liquid nitrogen and 
stored at -80°C. DNA and RNA were extracted as described (17). The proteomic study 
included 4 male patients (mean age 77, range 72-82) with HCC developed on chronic viral 
hepatitis C (stage F3 for 3 patients and F2 for one patient, according to Metavir classification 
(18)). In addition, HCC samples from 96 patients related to various etiologies were used for 
quantitative RT-PCR analysis and immunohistochemistry. The main clinical and pathological 
characteristics are indicated in Table 1. Six normal liver samples taken at distance from 
benign liver tumors were used as controls in quantitative RT-PCR and 
immunohistochemistry. Survival analysis included 45 patients treated with a complete tumor 
resection before 2002; patients treated with liver transplantation, incomplete resection, or 
deceased in the post-operative period were excluded.  
 
Proteomic analysis  
Four tumoral samples were compared to matched non-tumor samples using 2D 
electrophoresis as previously described in detail (6).  
 
Real-time RT-PCR 
Liver samples. One µg of total RNA was reverse transcribed using the High capacity Archive 
kit and random hexamers (Applied Biosystems) and 5 µl of cDNA corresponding to 10 ng of 
reverse transcribed RNA were analyzed by TaqMan PCR analysis, in duplicate, using the ABI 
PRISM® 7900HT System (Applied Biosystems). Pre-developed sequence detection reagents 
specific for human RUVBL2 gene (Applied Biosystems) were used as described (17) using the 
2-∆∆CT method (19). Briefly, gene expression results were first normalized to internal control 
ribosomal 18S. Then, results in HCC samples were expressed as a ratio relatively to the mean 
expression level in non-tumor samples. We also measured the mRNA level of expression for 
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c-myc, GLUL (encoding glutamine synthase) and GPR49 (encoding an orphan nuclear 
receptor), two well known β-catenin target genes, as previously described (20). Finally, 
mutations in the CTNNB1 gene coding for β-catenin were searched as described (2). 
Cellular samples. Total RNA was extracted using Trizol® reagent (Invitrogen). One µg of total 
RNA was reverse transcribed using the Superscript™ II reverse transcriptase (Invitrogen) and 
random hexamers (Roche). Five µl of cDNA corresponding to 5 ng of reverse transcribed 
RNA were analyzed by SYBR Green PCR analysis using the Mx4000® Multiplex 
Quantitative PCR System (Stratagene). PCR mixes were made such that each 25 µl reaction 
contained 12.5 µl of iQ Sybr Green Supermix (BioRad), 5 µl of diluted cDNA template and 
0.3 µM sense and antisense gene primers. Primer sequences are shown in supplementary 
Table 1. The reactions were incubated at 95°C for 3 min, followed by 40 cycles of 95°C for 
15s and 65° for 15s. Data analysis was performed using the Mx4000 software version 4.2 
(Stratagene). Gene expression results were first normalized to internal control RLP0. Relative 
levels of expression were quantified by calculating 2-ΔΔCt. Results were expressed as a ratio 
relatively to the expression level in non-transfected cells. 
 
Immunohistochemistry 
Twenty samples of HCC and their corresponding non tumoral liver were evaluated by 
immunohistochemistry, together with 6 normal liver samples. Formalin-fixed, paraffin-
embedded sections were used. Following dewaxing and dehydration, sections were submitted 
to antigen retrieval using a steam cooker in citrate buffer 0.01 M pH 7 for 10 min, then 
permeabilized with methanol for 1h. The immunostaining procedure was carried out in an 
Autostainer (Dako). Endogenous peroxidase was inhibited with 3% H2O2 in methanol and 
sections were treated with 2N HCl for 30 min at 37°C. Non specific sites were saturated with 
3% BSA and sections were incubated with a mouse monoclonal anti-RUVBL2 antibody (BD 
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Biosciences) diluted 1:50. After washing, the signal was amplified with the EnvisionTM  
reagent coupled to horseradish peroxidase. The staining was revealed with diaminobenzidine. 
 
Construction of a cell line with overexpression of RUVBL2 
We used the human hepatocellular carcinoma cell line HuH7. A Flag-tagged RUVBL2 cDNA 
was placed under the control of the MND promoter as follows. The MND promoter 
(Myeloproliferative sarcoma virus enhancer, Negative control region deleted, dl587rev 
primer-binding site substituted) was removed from a lentiviral construct (21). The 
pRRLSIN.cPPT-PGK-WPRE, a self-inactivating human immunodeficiency virus type-1 
(HIV-1)-based vector containing the central polypurine and termination tract (cPPT) and the 
woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), was provided by 
D. Trono (Geneva, Switzerland). In short, we replaced the PGK promoter with the MND 
promoter. Then, a cDNA coding human RUVBL2 with a N-terminal FLAG tag (8) was 
cloned downstream of the MND promoter, leading to the TMRepW vector. As a control, we 
constructed the TMEW vector by cloning the EGFP cDNA instead of the RUVBL2 sequence. 
VSV-G pseudotyped lentivectors were produced by triple-transient transfection of 293T cells 
(22). Titers were determined by transducing 293T cells with serial dilution of lentiviral 
supernatant and analyzed for EGFP expression 5 days later. Finally, HuH7 cells were 
transduced with lentiviral vectors at a multiplicity of infection of 20 and/or 10 in DMEM 10% 
FCS medium with 8µg/mL protamine sulfate (Sigma, St Louis, MI). Infection efficiency was 
checked by testing for EGFP expression by flow cytometry. 
 
Transient transfection of siRNA 
We used siRNAs targeting 2 separate sequences from RUVBL2 mRNA. The sequence 5’-
GATGATTGAGTCCCTGACCAA-3’ corresponds to nucleotides 552-572 from the reference 
H
AL author m
anuscript    inserm
-00173425, version 1
Rousseau et al.- HEP-06-1012 
   
 
8 
sequence (gi:9367026) and will be referred to as siR1, while the sequence 5’-
GAAGATGTGGAGATGAGTGAG-3’ corresponds to nucleotides 1153-1173 and will be 
referred to as siR2. As a control, we used a scrambled sequence from siR2, 5'-
GGATGTAAGTGGGAAAGTGGA-3’. The corresponding oligonucleotides were bought 
from Eurogentec (Searing, Belgium) as duplexes and were transfected into HuH7 cells with 
Lipofectamine (InVitrogen, Cergy Pontoise, France) at a concentration of 125 nM. 
 
Western blot 
Cell extracts and tissue samples were prepared in RIPA buffer as described (23). Protein 
concentration was measured with a BioRad assay. Samples were analyzed by Western blot 
with either a rabbit polyclonal (8) or a mouse monoclonal antibody (BD Biosciences 
Pharmingen) to RUVBL2 (# 612482), or an anti-Flag M2 antibody (Sigma). Normalization 
was achieved by rehybridization with an anti-beta-actin antibody. Signals were acquired on a 
Macintosh computer using a Kodak Digital Science DC 120 digital camera and quantified 
using the NIH Image software. 
 
Cell proliferation  
Proliferation of cells transfected with siRNAs was assessed by counting adherent cells at 
varying times using a Coulter counter (Beckman Coulter) in duplicate wells.  
DNA synthesis was measured by quantifying the incorporation of bromodeoxyuridine (BrdU). 
Briefly, cells were incubated for 2 h with 15 mM BrdU. They were fixed with methanol, 
treated with 2N HCl and incubated with a rat anti-BrdU antibody (Serotec) followed by an 
Alexa fluor 488 labeled secondary antibody (InVitrogen Molecular Probes). Nuclear DNA 
was stained with DAPI. BrdU-positive cells were counted under a fluorescence microscope in 
at least 15 non overlapping fields and results were expressed as a percentage of total cells. 
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We also measured the percentage of cells expressing the proliferation antigen Ki67 (24). 
Briefly, cells were fixed with 0.4 % paraformalehyde, permeabilized with 0.02 % saponin, 
then incubated with a FITC-labeled Ki67 antibody (Dako) and analyzed by flow cytometry. 
Anchorage-independent growth was assayed as follows. Flag-RUVBL2 expressing cells or 
control cells (10,000) were suspended in DMEM containing 10 % FCS and 0.2% agar 
(overlay) on top of an agar underlay (DMEM/10% FCS/0.5% agar) in a 60 mm diameter dish. 
Cells were fed twice a week with 2 ml of overlay medium, and the area of colonies was 
measured after 2 weeks using Image J software (http://rsb.info.nih.gov/ij/). Thirty different 
fields (5X) were scored. The experiments were done in triplicate.  
 
Assay for cell viability 
Cells were seeded at a density of 6,000/well in 96w plates. After 7h, they were treated with 
the indicated agonists for 17h. Cell viability was assessed by incubating with DMEM 
containing 1 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
during 2 hours at 37°C as described (25). The linearity of the assay over the range of cell 
densities was checked in preliminary experiments. 
 
Apoptosis 
Cells were fixed using PFA 4% in PBS at 4°C during 10 min, then permeabilized with 0.5 % 
Triton X-100. They were stained with DAPI (Sigma, 0.5 µg/ml) together with a rabbit anti-
human active caspase 3 antibody (R&D systems, 0.25 µg/ml). After washing, cells were 
incubated with goat anti-rabbit Alexa 488 (Molecular Probes) and examined under a Zeiss 
Axioplan microscope.  
The extent of DNA fragmentation was quantified with flow cytometry as described (26). 
Briefly, trypsinized cells were resuspended in 0.1% sodium citrate containing 0.1% Triton X-
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100, 50 µg/ml propidium iodide and 100 µg/ml RNAse. Cell DNA content was measured 
using a FACScalibur (BD Biosciences, San Jose, CA, USA). 
We also quantified caspase 3 activity using a colorimetric kit from Chemicon (Temecula, 
California), according to instructions from the supplier. Briefly, cleared cell extracts were 
incubated with the caspase 3 substrate and optical density was read at 405 nm in a Dynatech 
microplate reader (MTX Lab Systems, Inc., Vienna, VA). 
Finally, we assessed Bak-1 and Bax activation using antibodies (Bak- 1 : AM03, Calbiochem, 
VWR International, Fontenay-sous-Bois, France ; Bax : 6A7 BD Pharmingen, Le Pont de 
Claix, France) that recognizes the N-terminus of the proteins made accessible following the 
conformational changes upon activation. This was done using flow cytometry as described by 
others (27, 28). 
 
Xenografts 
12 weeks-old Rag2/γc mice (gift of J Di Santo (29)) were housed in germ-free conditions. The 
study was performed in accordance with the European Community Standards on the Care and 
Use of laboratory Animals. Mice were injected subcutaneously with 2x 106 cells in the flank. 
Tumor size was monitored with calipers. Tumor volume was estimated as (D2xd)/2, where D 
is the large diameter and d is the small diameter of the tumor. At the end of the experiment, 
tumors were harvested and a part was snap-frozen in liquid nitrogen.  
 
Statistical analysis 
Differences between means were assessed using the Mann-Whitney test. When comparing 
multiple means, we used an analysis of variance. A p value less than 0.05 was considered 
significant. Correlation between mRNA level of expression and qualitative variables were 
calculated using the non-parametric Kruskal-Wallis test with STATA software (Stata 
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corporation, Texas). Age of patients and diameter of tumors were partitioned using median. 
Survival analyses were performed using Cox model to fit maximum-likelihood proportional 
hazards models using STATA software. 
 
Results 
RUVBL2 expression in HCC 
Proteome analysis was performed using 2DE gel electrophoresis comparing 4 HCC related to 
HCV infection with their matched non-tumor tissues. One of the 850 protein spots detected 
was increased in all 4 cases of HCC with a mean tumor/non tumor ratio of 4.1 (range 2.8-6.9) 
(Fig. 1A). It was identified as RUVBL2, based on the detection of two peptides 
(GLGLDDALEPR and LLIVSTTPYSEK) and detailed MS/MS analysis as previously 
described (6). Overexpression of RUVBL2 was confirmed by western blot in these 4 cases 
(Fig. 1B). 
The cellular localization of RUVBL2 was assessed by immunohistochemistry in 20 samples 
of HCC from various etiologies and in the corresponding non tumoral livers, as well as in 4 
cases of histologically normal livers. In normal liver, RUVBL2 expression was found in a 
variable fraction of hepatocytes, where it was faint and restricted to the nucleus; in addition, 
RUVBL2 staining was intense in bile duct cells where it was found in the nucleus and 
cytoplasm, and was also observed in some lymphocytes, either sinusoidal or portal (Fig. 2A). 
The same staining pattern, in terms of distribution and intensity, was seen in all samples of 
peri-tumoral livers, whether cirrhotic or not (Fig. 2C and 2F). In sharp contrast, RUVBL2 was 
overexpressed in all analyzed HCC (Fig. 2C), where in addition it showed a definite 
cytoplasmic staining that varied from faint to intense (Fig. 2D-E); in addition, nuclear staining 
of tumor cells was in most cases stronger than that of peri-tumoral hepatocytes (Fig. 2D-E). It 
should be noted however that the staining pattern was often heterogeneous within a given 
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tumor (Fig. 2C). In order to search for detailed clinico-pathological correlations, we measured 
RUVBL2 mRNA expression in a larger series of 96 well-annotated HCC related to various 
risk factors. We first confirmed in this series the increased expression of RUVBL2 transcripts 
in 72/96 HCC, ranging from 1.5 to 6.6 when compared with non-tumor liver tissues that 
ranged from 0.42 to 1.5 (p= 0.002, Fig. 3A). RUVBL2 expression was significantly lower in 
HBV related HCC (Fig. 3B) whereas it was significantly higher in poorly differentiated 
tumors proportionally to the Edmondson grade (Fig. 3C). In contrast, the other clinical and 
pathological characteristics mentioned in Table 1 were not significantly associated to 
RUVBL2 expression level. Using a Cox model analysis without partition, we showed a 
significant relationship between a high level of RUVBL2 in tumors and shorter overall 
survival of patients following surgery (p= 0.02; relative risk 1.4, standard error 0.2, CI 95% 
1.05-1.85). In contrast, we did not find a difference of RUVBL2 expression in β-catenin-
activated HCC when compared to CTNNB1 non-mutated HCC (Fig. 3D). Accordingly, in the 
96 HCC samples, we did not observe any correlation between the expression level of 
RUVBL2 and of β-catenin target genes (GLUL and GPR49, data not shown). In addition, c-
myc transcript levels were measured in a subset of 42 patients and no correlation was found 
with RUVBL2 levels (r2 = 0.01, p = 0.5, not shown). 
Finally, the whole coding sequence of RUVBL2 was PCR-amplified in 10 HCC samples and 
no mutation leading to a change in amino-acid sequence was identified (not shown).  
Thus, because RUVBL2 over-expression was found in the vast majority of HCC and was 
related to the aggressiveness of tumors, we explored the role of RUVBL2 in tumorigenesis by 
modulating its expression in the HCC cell line HuH7. 
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Down-regulation of RUVBL2 expression reduced cell growth and increased apoptosis 
Down-regulation of RUVBL2 expression was obtained using transient transfections of siRNA 
duplexes. Quantitative RT-PCR showed that as soon as 24 h after transfection, RUVBL2 
transcripts were reduced to 33.5 ± 9.8% with siR1 and 29.5 ± 14.4% with siR2, as compared 
to 104.4 ± 15.4% with the scrambled sequence (n = 6, p = 0.02). In addition, as shown on Fig. 
4A, the two targeting siRNAs led to a large decrease in RUVBL2 protein expression that 
reached more than 90% with siR1 and close to 80% with siR2. In both cases, the decrease was 
stable for at least 6 days.  
We next evaluated the effect of RUVBL2 down expression on cell growth. Following a slight 
reduction in cell numbers observed at Days 3-4 post-transfection with either scrambled or 
RUVBL2 siRNAs (siR1 and siR2), a marked and significant reduction in cell numbers was 
observed in siR1 and siR2 transfected cells until day 6 when compared with non transfected 
or scrambled transfected cells (p<0.001, Fig 4B); the reduction was more drastic with siR1 
than siR2. This reduction was linked to a decreased cell proliferation as evidenced by the 
measure of BrdU incorporation : at Day 4 post-transfection, there was an average of 37.0 ± 
1.5 % labeled cells with the scramble oligonucleotide, as compared to 21.7 ± 1.0 % with siR1. 
The mean decrease with siR1 was 41.0 ± 4.4 % (n = 3, p < 0.04). Similarly, the percentage of 
cells positive for Ki67 was significantly decreased by both siR1 and with siR2 (Fig. 4C). 
In parallel, we observed that down regulation of RUVBL2 expression was associated with a 
high number of cells floating in the supernatant (not shown), suggesting that the cells may 
undergo apoptosis. This was confirmed by staining nuclear DNA with DAPI showing 
characteristic pictures of fragmented nuclei in RUVBL2 siRNA-transfected cells (Fig. 4E), as 
compared to scrambled (Fig. 4D). Simultaneous staining of the cells with an antibody specific 
for activated caspase 3 demonstrated that many cells transfected with RUVBL2 siRNAs 
showed an activation of this apoptotic pathway (compare Fig. 4G and 4F). DNA 
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fragmentation was quantified with flow cytometry that showed a significantly higher 
percentage of fragmented DNA at Day 6 post-transfection in cells transfected with siR1 or 
siR2 than in scrambled-transfected cells (ANOVA, p< 0.001; Fig 4J). Similarly, 
quantification of caspase 3 activity with a colorimetric assay showed a significantly increased 
activity with both siR1 and siR2, as shown on Fig. 4K (ANOVA, p< 0.005).  
In order to gain insight into the mechanisms of apoptosis, we measured the activation of the 
pro-apoptotic Bcl-2 family members Bax and Bak-1. These 2 proteins undergo a 
conformational activation that can be evidenced using conformation-sensitive antibodies in 
flow cytometry. As shown on Fig. 5A-B, the number of cells showing activation of either Bax 
or Bak-1 was significantly increased upon down-regulation of RUVBL2. In addition, we also 
show a significantly increased expression of the transcripts of Bak-1 and of the other pro-
apoptotic proteins Bad and Bid at Days 3 and 4 post-transfection of RUVBL2 siRNA, and of 
Bcl-xS at Day 4. There was also a trend towards an increase for Bax and PUMA, whereas no 
changes were seen for the anti-apoptotic gene Bcl-xL (Fig. 5C-D). 
 
Up-regulation of RUVBL2 expression promotes in vitro anchorage-independent cell growth 
and in vivo tumorigenesis 
Here, Flag-tagged RUVBL2 was overexpressed under the control of the MND promoter in a 
lentiviral vector. Flag-tagged RUVBL2 could be easily detected and discriminated from 
endogenous RUVBL2 on Western blots due to its slower gel mobility. The factor of 
overexpression of RUVBL2 protein, assessed by making the sum of the intensities of the 
endogenous and the Flag-tagged RUVBL2 bands, was of only 1.2 in 2 independent 
transductions. This was due at least in part to a decrease in endogenous RUVBL2 levels in 
Flag-RUVBL2-infected cells (Fig. 6A). Several preliminary experiments allowed us to check 
that Flag-tagged RUVBL2 behaved similarly as endogenous RUVBL2 : western blot of 
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nuclear and cytosolic extracts showed that both forms segregated alike in these 2 
compartments; immunoprecipitation of Flag-tagged RUVBL2 pulled down expected partners 
(RUVBL1 and β-catenin (9)) indicating that the tagged protein was correctly incorporated 
into supra-molecular complexes (data not shown). 
The growth rate on plastic of Flag-RUVBL2-expressing cells was compared to that of control 
EGFP-transfected cells. No differences in cell numbers were seen after 1, 2 or 3 days in serum 
concentrations ranging from 0.5 to 10% (data not shown). However, when anchorage-
independent growth was measured in a soft agar assay, we found a large difference in the 
growth ability of Flag-RUVBL2-expressing cells, as shown by a significant increase in the 
surface of the colonies (Fig. 6B, p< 0.03, Kruskal-Wallis). 
In subsequent experiments HuH7 cells were challenged with an apoptotic stimulus, C2 
ceramide (30), and cell survival was assessed with the MTT assay. At every concentration of 
C2 ceramide tested, cells expressing Flag-RUVBL2 were slightly less susceptible to cell death 
than control cells. The difference was statistically significant except for the highest 
concentration of C2 ceramide when most cells were dead (Fig. 6C). Furthermore, when the 
extent of DNA fragmentation, as an evidence for apoptosis, was examined, cells expressing 
Flag-RUVBL2 exhibited a significant protection over a range of C2 ceramide concentrations, 
as compared with control cells (Fig. 6D). The fractional reduction in apoptosis as compared to 
control cells was 27.2 ± 6.0%, 19.3 ± 8.5% and 28.7 ± 3.3% at 20, 40 and 60 µM C2 
ceramide, respectively. 
Finally, cells transduced with either EGFP or Flag-tagged RUVBL2 were injected to 
immunocompromised mice (n = 20 in each group). Although there was no significant 
difference in the incidence of tumors in both groups (85.0 vs 94.7% in EGFP and RUVBL2 
groups, respectively), animals injected with Flag-RUVBL2-expressing cells developed 
significantly larger tumors than control animals (Fig. 6E, p =0.016 by ANOVA). Similar 
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results were obtained in another experiment using cells from an independent transduction with 
the viral vectors. When at the end of the experiment, tumors from surviving animals were 
removed and analyzed by Western blot, the persistence of Flag-RUVBL2 expression was 
confirmed in every tumor in the Flag-RUVBL2 group by the detection of a doublet upon 
blotting with RUVBL2 antibody, and by the detection of the Flag epitope (Fig. 6F). This also 
showed the persistent decrease in endogenous RUVBL2. 
 
Discussion 
Here, we show that RUVBL2 is up-regulated in a majority of HCCs. This over-expression is 
significantly associated with the differentiation grade of the tumors and RUVBL2 over-
expression can be considered as a marker of poor prognosis. Moreover, our results strongly 
suggest that RUVBL2, a protein with no specific function yet ascribed in human, may play an 
essential role in liver carcinogenesis. To our knowledge, our findings are the first to report the 
deregulation of RUVBL2 expression in cancer. Our immunohistochemical data indicate that 
hepatocyte RUVBL2 expression appear increased in every HCC studied, although to a various 
extent. It is likely that tumor/non tumor ratios obtained with RT-PCR are artefactually low 
because of the high-level expression of RUVBL2 seen in the ductular proliferation of the non 
tumoral, cirrhotic livers (Fig. 2F). 
Cells where RUVBL2 was down-regulated showed a decreased proliferation rate, 
concomitant with a strong induction of apoptosis, as evidenced by the occurrence of DNA 
fragmentation and increased caspase 3 activity. In addition to HuH7, we observed a similar 
phenotype in 2 other HCC cell lines, Hep3B and FOCUS (not shown). Thus, RUVBL2 
deficiency leads to liver cancer cell growth arrest and to apoptosis. RUVBL2 was previously 
shown to be also required for growth and survival of yeast (7, 31, 32). Our data have shed 
some light on the mechanisms of apoptosis induced by RUVBL2 deficiency. We show that 
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RUVBL2 downregulation is associated with the increased conformational activation of the 
pro-apoptotic proteins Bak-1 and Bax. In quiescent cells, Bak-1 and Bax are maintained in an 
inactive state through interactions with the anti-apoptotic proteins Bcl-xL and Mcl-1 (33). 
Their activation leads to the permeabilization of the outer membrane of mitochondria, 
resulting in cytochrome c release and caspase activation. In addition to protein activation, we 
also found that Bak-1 and Bax transcripts were upregulated, together with those of Bid, a 
BH3-only protein involved in Bak-1 and Bax activation (34, 35), whereas interestingly, Bcl-
xL levels did not increase. These changes were seen as early as Day 3, well before the 
occurrence of cell death, suggesting that they may play a causal role. We thus propose that 
apoptosis induced by RUVBL2 depletion is linked to the activation of pro-apoptotic Bcl-2 
family members. Such a mechanism could be amplified because of the transcriptional 
upregulation of these proteins. Whether the related genes are direct targets of RUVBL2 
remains to be determined.  
We then transduced cells with a lentiviral construct driving the expression of Flag-RUVBL2. 
This led to only a modest increase in total expression of RUVBL2 which was not the 
consequence of a low level of transduction or of insufficient promoter activity, since 
RUVBL2 mRNA levels were 7.5 ± 2.2-fold higher in transduced cells as compared to control 
cells (not shown). The post-transcriptional regulation responsible for this is currently under 
study. Despite this modest 20% increase, Flag-RUVBL2 cells grew better in soft agar than 
control cells. Moreover, when Flag-RUVBL2 expressing cells were injected to 
immunocompromised mice, tumors grew eventually to a larger size. The mechanism for this 
effect remains to be evaluated in more depth, but may be partly related to a better ability of 
Flag-RUVBL2 expressing cells for survival in stressful conditions. We indeed found that 
Flag-RUVBL2 expressing cells were less susceptible to cell killing induced by the pro-
apoptotic agent C2 ceramide. Although the protection was limited, it was in the range of 20-
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30% at various concentrations of C2 ceramide, thus commensurate with the 20% 
overexpression of RUVBL2.  
RUVBL2 is known to physically interact with β-catenin (9). Several publications have shown 
that RUVBL2 behaved as an antagonist of the transcriptional activity of the β-catenin-
TCF/LEF complex (9, 15). Since β-catenin is considered an oncogene in HCC, these results 
appear counter-intuitive. However, recently, RUVBL2 was also found to be required for the 
repressing effect of β-catenin on the transcription of the anti-metastatic gene KAI-1 (36), that 
is frequently down-regulated in HCC (37). In our study of a large number of HCC samples, 
there were however no correlations between the level of expression of RUVBL2 and of 
β−catenin target genes. It is thus likely that additional mechanisms, independent of β-catenin, 
may also explain the oncogenic properties of RUVBL2. Indeed, RUVBL2 has been found in 
supra-molecular complexes that do not include β-catenin (11), and β-catenin-independent 
functions of RUVBL2 have already been identified (15). It is also noteworthy that RUVBL2 
is required for the viability of yeast (7, 31, 32), an organism devoid of β-catenin. In this 
context, one of the salient findings of this study was that in addition to its overexpression in 
HCC, RUVBL2 was also found in the cytoplasm of HCC cells. This suggests that RUVBL2 
serves specific cancer-related functions in the cytoplasm of tumor cells.  
We have thus identified a new protein up-regulated in HCC. In vitro and in vivo results 
suggest that RUVBL2 could play an important role in liver carcinogenesis. Since mutations in 
the ATPase domains of RUVBL2 abolish its biological activity (7, 31, 32), targeting of its 
activity with specific inhibitors may offer a new therapeutic avenue in cancer management. 
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Figure legends 
Figure 1 : RUVBL2 expression in hepatocellular carcinoma 
A : Zoom on an area of 2-dimensional gels showing a spot more abundant in tumoral (T) than 
non-tumoral (NT) tissue. Note that other spots in the area are of similar intensity in 
both samples. 
B : Western blot of RUVBL2 expression in the 4 samples of HCC and paired non tumoral 
liver used for proteomic analysis. The blot was subsequently rehybridized with a β-
actin antibody. 
 
Figure 2 : Immunohistochemical detection of RUVBL2 in liver samples 
A :  Immunostaining of RUVBL2 in a normal liver at distance of an hemangioma. 
Hepatocytes nuclei are irregularly and mildly stained; in addition biliary cells of an 
interlobular bile duct in a portal tract show a strong nuclear and cytoplasmic staining 
(arrow). Inset : higher magnification from another normal liver showing the 
heterogeneous nuclear staining as well as the intense bile duct cells staining. 
B : A serial section incubated with a non immune IgG shows no staining. 
C : Immunostaining of HCC and surrounding cirrhotic liver (Cir) demonstrates the 
overexpression of RUVBL2 in HCC and shows that the staining of tumoral 
hepatocytes is heterogeneous, from mild to strong 
D : High magnification of a zone from the HCC shown in 2C illustrates a strong staining of 
cytoplasm 
E : High magnification of another HCC case with less intense although definite cytoplasmic 
staining 
H
AL author m
anuscript    inserm
-00173425, version 1
Rousseau et al.- HEP-06-1012 
   
 
25 
F : In surrounding cirrhotic nodules, hepatocytes show only a nuclear staining. Biliary cells of 
the ductular reaction (arrows) are intensely stained. Some lymphocytes in the fibrous 
tissue are also stained (arrowhead). 
 
Figure 3 : Correlations between RUVBL2 mRNA levels and clinico-pathological features 
of HCC 
RUVBL2 mRNA level was measured by RT-QPCR. Gene expression results were first 
normalized to internal control ribosomal 18S in all samples. Then, results in HCC samples 
were expressed as a ratio relatively to the mean expression level in  a pool of 15 non-tumor 
samples. 
A : differences between non-tumor and tumor samples in the series of 96 HCCs 
B : RUVBL2 expression according to HBV status (HBV infected, n = 9; non infected, n = 78) 
C : RUVBL2 expression according to tumor grade (grade I, n = 3; grade II, n= 37; grade III, 
n= 47, grade IV, n= 6) 
D : RUVBL2 expression in relation to the presence of β−catenin mutations 
 
Figure 4 : Knock-down of RUVBL2 expression leads to reduced proliferation and cell 
death 
A : Western blot of RUVBL2 expression. HuH7 cells were transfected with siRNA duplexes 
at Day 0. At indicated times, cells were lysed and processed for Western blot with anti-
RUVBL2 and anti-β-actin antibodies.  
B : Cell proliferation was measured with a Coulter counter at indicated times post-transfection 
of siRNA duplexes. Shown are the mean ± SEM of 3 experiments conducted in duplicate. 
Symbols are as follows : lozenges (non transfected), triangles (scrambled), open squares 
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(siR1), closed squares (siR2). The growth of siR1 and siR2 transduced cells was significantly 
reduced as compared to controls (p<0.001 by ANOVA). 
C- At Day 4 post-transfection, cells were labeled with Ki67 antibody and the percentage of 
labeled cells was measured with flow cytometry. NT = non transfected. The percentage of 
labeled cells was significantly reduced with siR1 and siR2 as compared to both controls (p < 
0.002 by ANOVA). 
D-I : At Day 6 post-transfection of scrambled siRNA (D, F, H) or RUVBL2 siRNA (siR1, E, 
G, I), cells were simultaneously stained with DAPI (D, E) and antibody to activated caspase-3 
(F, G). Arrows indicate cells with fragmented nuclei and cytoplasmic staining for activated 
caspase-3. H and I are merged pictures. 
J : At Day 6 post-transfection, the percentage of cells with fragmented DNA was measured by 
flow cytometry following propidium iodide staining. Results are expressed relatively to the 
values found in scrambled-transfected cells and are the mean ± SD of 3 experiments in 
duplicate. White bar : control ; grey bar : siR1 ; black bar : siR2. DNA fragmentation was 
significantly increased in siR1 and siR2 transduced cells as compared to controls (p<0.001 by 
ANOVA). 
K : At Day 6 post-transfection, caspase 3 activity was measured with a colorimetric substrate. 
Results are expressed relatively to the values found in scrambled-transfected cells and are the 
mean ± SD of 3 experiments in duplicate. White bar : control ; grey bar : siR1 ; black bar : 
siR2. Caspase-3 activity was significantly increased in siR1 and siR2 transduced cells as 
compared to controls (p<0.005 by ANOVA). 
 
Figure 5 : RUVBL2 downregulation induces pro-apoptotic gene expression 
A : At 5 days following siRNA transfection, cells were analyzed by flow cytometry with 
conformation-sensitive Bak-1 (left panel) of Bax (right panel) antibodies. Gray peaks indicate 
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scramble-transfected cells, black line, siR1-transfected cells. Non-transfected cells are not 
shown for clarity but showed identical results as scramble-transfected cells. 
B : Quantification of 3 independent transfection experiments. One-way analysis of variance 
showed that results differed overall significantly between groups (p = 0.0002 for Bak-1, p = 
0.006 for Bax). Significative differences between individual groups were assessed with the 
post-hoc Tukey’s test and are shown on the graphs. 
C, D : Cells were transfected with siRNAs as in Fig. 4. Total RNA was extracted at Days 3 
(C) and 4 (D), and gene expression was measured using real time RT-PCR. Results were 
normalized on the basis of the expression of the RLP0 gene and on the levels of the non 
transfected samples. Black bars indicate non transfected cells, white bars, scramble-
transfected cells, and striped bars, cells transfected with siR1. The graph shows the mean ± 
SD of 3 independent experiments. Numbers indicate the p value using ANOVA. 
 
Figure 6 : Up-regulation of RUVBL2 expression enhances anchorage-independent 
growth, protects against apoptosis, and leads to more rapidly progressive tumors in vivo 
A: Cell lysates from cells transduced with the control lentivirus (lane 1) or the Flag-RUVBL2 
vector (lane 2) were examined by Western blot with an anti-RUVBL2 antibody. The blot was 
rehybridized with an antibody to β-actin.  
B : Control (black bar) or Flag-RUVBL2-expressing cells (open bar) were seeded in soft agar 
at clonal density. The surface area of colonies was measured after 2 weeks. Results are 
expressed relatively to the values found in control cells and are the mean ± SD of 3 
experiments in triplicate. 
C : Control (closed squares) or Flag-RUVBL2-expressing cells (open squares) were incubated 
with the indicated concentrations of C2 ceramide for 15-17h. Cell viability was assessed with 
the MTT assay. Results are expressed as the percentage of viability as compared to untreated 
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cells, and are shown as mean ± SEM of 5 experiments in triplicate. One-way analysis of 
variance showed that results differed overall significantly between groups (p< 0.001). 
Significative differences between individual groups were assessed with the post-hoc Tukey’s 
test (* : p < 0.05; # p < 0.001). 
D : Control (black bars) or Flag-RUVBL2 expressing cells were incubated with the indicated 
concentrations of C2 ceramide for 17h and the percentage of cells with fragmented DNA was 
measured by flow cytometry following propidium iodide staining. Results are the mean ± 
SEM of 3 experiments. One-way analysis of variance showed that results differed overall 
significantly between groups (p< 0.001). Asterisks indicate significative differences between 
individual groups by the post-hoc Tukey’s test (p< 0.01). 
E : Control (closed squares) or Flag-RUVBL2-expressing cells (open squares) were injected 
subcutaneously to immunocompromised mice (20 mice per group). Tumor growth was 
monitored periodically. Results are expressed as mean tumor volume ± SEM. The 2 groups 
differed significantly by ANOVA.  
F : A subset of tumors were analyzed at the end of the experiment by Western blot with 
antibodies to RUVBL2 (upper panel), Flag (middle panel) or β-actin (lower panel). 
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Table 1. Characteristics of patients and tumors (n=96) 
Clinical characteristics 
Age (mean ± SD) 64.6 ±10.6 years 
Gender (male) 87.5% 
AFP < 20 ng/ml 63% 
Cirrhosis or chronic active hepatitis 60% 
HBV infection 10% 
HCV infection 25% 
Alcohol  55% 
Hemochromatosis 3% 
Tumors characteristics 
Diameter (mean ± SD ) 7.1 ± 5 cm 
Intact capsule 16% 
Satellite nodule 41% 
Edmondson grade III or IV 57% 
Microscopic vascular embolus 36% 
CTNNB1 mutations 35% 
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Supplementary Table 1. Sequences of primers used for PCR 
Gene Primers sequence  
BAD U : 5’ CCC AAC CTC TGG GCA GCA C 3’ 
L : 5’ CGA GGA AGT CCC TTC TTA AAG GAG T 3’ 
BAK-1 U : 5’ CAA GAT TGC CAC CAG CCT GTT 3’ 
L : 5’ AGG CCA TGC TGG TAG ACG TGT A 3’ 
BAX U : 5’ GTG CCT CAG GAT GCG TCC A 3’ 
L : 5’ ACG GCG GCA ATC ATC CTC T 3’ 
PUMA U : 5’ AGTACGAGC GGC GGA GAC A 3’  
L : 5’ GGA GTC CCA TGA TGA GAT TGT ACA G 3’ 
BCL-xS U : 5’ GAC ATC CCA GCT CCA CAT CAC 3’ 
L : 5’ GTT CCA CAA AAG TAT CCT GTT CAA A 3’ 
BCL-xL U : 5’ TGA ATG ACC ACC TAG AGC CTT GGA 3’ 
L : 5’ GGA ACC AGC GGT TGA AGC GT 3’ 
BID U : 5’ CGT CCT TGC TCC GTG ATG TCT T 3’ 
L : 5’ TCC GTT CAG TCC ATC CCA TTT C 3’ 
RLP0 U : 5’ GGC GAC CTG GAA GTC CAA CT 3’ 
L : 5’ CCA TCA GCA CCA CAG CCT TC 3’ 
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